Regenxbio reported consistent, favorable safety signals and functional improvements for its Duchenne muscular dystrophy (DMD) gene therapy candidate ahead of an impending pivotal data readout. Company presentations at the Muscular Dystrophy Association conference highlighted stable cardiac metrics and functional gains in the phase I/II Affinity trial. Management emphasized a clean safety profile across treated patients and continued functional benefit in ambulatory measures; Regenxbio is positioning the data to support regulatory discussions as the program moves toward a pivotal milestone. Investors and competitors are watching closely because the outcome will affect the regulatory environment for systemic AAV gene therapies in neuromuscular disease and could shift industry expectations around risk management and long-term monitoring for vector-linked adverse events.